Abiopharma

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

Labcorp to Announce Second Quarter Financial Results on July 24, 2025

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on M

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

Windtree Advances Lower Cost Manufacturing of PHEXXI,Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel

Alto Ingredients, Inc. Names Gilbert Nathan Chair, Dianne Nury Vice-Chair and Elects Two New Directors

Aclaris Therapeutics to Participate in the H.C.Wainwright Inflammation & Immunology Virtual Conference

Achieve Life Sciences Announces Proposed Underwritten Public Offering

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)